Advertisement


Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

2015 ASCO Annual Meeting

Advertisement

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.



Related Videos

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Prostate Cancer

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).

Cost of Care

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

Global Cancer Care

Tony Mok, MD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Asian Perspective

James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.

Prostate Cancer

Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

Advertisement

Advertisement




Advertisement